Table 2.

Prevalence for promoter hypermethylation of ASC/TMS1 in sputum
GroupMethylation status of ASC/TMS1 (%)Odds ratio (95% confidence interval)
Smokers2 of 85 (2.4)Reference
Stage I lung cancer patients3 of 18 (16.7)7.2 (1.1-48.7)
Resected stage I lung cancer patients10 of 42 (23.8)11.0 (2.2-54.7)
Stage III lung cancer patients18 of 44 (40.9)28.6 (6.1-134.7)
Methylation status of sputum and histologic tumor type
Histologic typeMethylation status of ASC/TMS1 (%)
Stage III lung cancer patients
    Adenocarcinoma9 of 16 (56.2)
    Squamous cell carcinoma1 of 12 (8.3)
    Adenosquamous cell carcinoma0 of 1 (0)
    Large-cell carcinoma0 of 1 (0)
    NSCLC NOS *7 of 11 (63.6)
    Other0 of 1 (0)
    Unknown1 of 2 (50)
Stage I lung cancer patients
    Adenocarcinoma1 of 10 (10)
    Squamous cell carcinoma2 of 4 (50)
    NSCLC NOS *0 of 3 (0)
    Unknown0 of 1 (0)
Resected stage I lung cancer patients
    Adenocarcinoma5 of 27 (18.5)
    Squamous cell carcinoma3 of 8 (37.5)
    Large-cell carcinoma1 of 2 (50)
    NSCLC NOS *0 of 4 (0)
    Unknown1 of 1 (100)
  • * NOS, not otherwise specified.